Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR-T Program [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
See our latest analysis for Arcellx. That call from Wells Fargo lands after a choppy stretch, with a 1 month share price return of minus 27.36% and a year to date share price return of minus 16.81%. However, the 3 year total shareholder return is still up 121.17%, suggesting long term momentum remains intact despite recent volatility. If Arcellx's CAR T story has your attention, it is also worth seeing what else is happening across innovative healthcare stocks that could benefit from similar sentiment shifts. With Arcellx trading well below Wall Street targets despite fast growing revenue and a pivotal CAR T franchise taking shape, is this pullback mispricing its long term potential or accurately baking in execution and trial risk? Arcellx last closed at $65.51, and on a price to book basis the stock screens as expensive compared to both peers and the broader US biotech group. The price to book ratio compares a company's market value with the accounting value of its net ass
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Arcellx (NASDAQ:ACLX) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.MarketBeat
- Arcellx (NASDAQ:ACLX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.MarketBeat
- Arcellx: Funded Into 2028 With Strong Clinical Data [Seeking Alpha]Seeking Alpha
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $130.00 price target on the stock.MarketBeat
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.MarketBeat
ACLX
Earnings
- 11/5/25 - Miss
ACLX
Sec Filings
- 12/8/25 - Form 8-K
- 12/5/25 - Form SCHEDULE
- 11/17/25 - Form 4
- ACLX's page on the SEC website